Junshi Biosciences reports strong revenue growth, narrows Q3 losses

Shanghai Junshi Biosciences Co., Ltd. reported a 31.40% year-on-year increase in operating income for the third quarter of 2025, reaching 637.5 million yuan. For the first nine months of 2025, operating income surged by 42.06% to 1.81 bn yuan, primarily driven by strong sales of commercialized drugs. The company’s core product, toripalimab injection, generated approximately 1.495 bn yuan in domestic sales, marking a 40% year-on-year increase.

Net loss attributable to shareholders for the reporting period decreased to 183 million yuan, from a larger loss in the previous year, with the overall net loss for the nine months at 595.7 million yuan. Total assets stood at 11.69 bn yuan at the end of the reporting period, an 8.40% increase from the previous year-end. This improvement is attributed to enhanced management, cost control, and a focus on resource allocation.

The company's cash and bank balances, alongside financial assets for trading, amounted to a robust 3.27 bn yuan, indicating sufficient capital reserves. Notably, the supplemental new drug application for TUOYI® as a first-line treatment for HER2-expressing urothelial carcinoma was accepted by the NMPA during the period.